Charles River acquires Retrogenix
The leading solution for receptor identification and off-target screening
Respected globally, Retrogenix’s clients include the world’s top twenty pharma
Uncover primary receptors and off-targets
Retrogenix’s cell microarray technology is the most powerful solution for identifying the specific human plasma membrane and secreted proteins that are targeted by antibodies, proteins, small molecules, viruses, CAR T cells and other ligands. We discover high quality, exploitable drug targets and mechanisms of action for our global pharmaceutical clients as well as screening for potential off-targets to inform lead selection and generate high quality IND-enabling specificity data.
- High success rates
- High specificity
- Low false positive rates
- Rapid turnaround (as little as 3 weeks)
Our unrivalled technology identifies interactions both with cell surface receptors and secreted proteins by screening test ligands for binding against over 6,200 full length proteins that are individually over-expressed in human cells. This physiologically-relevant system, coupled with our broad protein coverage, allows even low affinity interactions to be detected with a high degree of sensitivity and specificity.
Retrogenix works with small biotechs and leading academic groups through to major pharmaceutical companies; we are currently helping the world’s top twenty drug developers to bring new therapeutics to market faster.